Supernus Pharmaceuticals (SUPN)
(Real Time Quote from BATS)
$30.88 USD
-0.23 (-0.74%)
Updated Sep 16, 2024 01:20 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Income Statements
Fiscal Year end for Supernus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 608 | 667 | 580 | 520 | 393 |
Cost Of Goods | 84 | 87 | 75 | 52 | 17 |
Gross Profit | 524 | 580 | 505 | 468 | 376 |
Selling & Adminstrative & Depr. & Amort Expenses | 529 | 534 | 419 | 294 | 228 |
Income After Depreciation & Amortization | -5 | 46 | 86 | 174 | 149 |
Non-Operating Income | 10 | 22 | 11 | 19 | 22 |
Interest Expense | 2 | 7 | 23 | 24 | 23 |
Pretax Income | 3 | 61 | 73 | 169 | 147 |
Income Taxes | 1 | 0 | 20 | 42 | 34 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 1 | 61 | 53 | 127 | 113 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 1 | 61 | 53 | 127 | 113 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 80 | 137 | 137 | 206 | 167 |
Depreciation & Amortization (Cash Flow) | 85 | 91 | 51 | 32 | 18 |
Income After Depreciation & Amortization | -5 | 46 | 86 | 174 | 149 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.51 | 61.68 | 54.36 | 53.69 | 53.82 |
Diluted EPS Before Non-Recurring Items | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
Diluted Net EPS (GAAP) | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
Fiscal Year end for Supernus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 168.33 | 143.64 | 164.31 | 153.88 | 135.56 |
Cost Of Goods | 17.92 | 16.31 | 19.63 | 19.60 | 21.09 |
Gross Profit | 150.41 | 127.34 | 144.69 | 134.28 | 114.47 |
SG&A, R&D, and Dept/Amort Expenses | 127.84 | 130.49 | 145.69 | 126.14 | 132.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 22.57 | -3.15 | -1.00 | 8.14 | -17.59 |
Non-Operating Income | 3.73 | 3.40 | 1.99 | 1.75 | 1.37 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.91 |
Pretax Income | 26.30 | 0.24 | 0.99 | 9.89 | -17.13 |
Income Taxes | 6.39 | 0.12 | -0.19 | 25.87 | -16.30 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 19.92 | 0.12 | 1.18 | -15.98 | -0.83 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 19.92 | 0.12 | 1.17 | -15.98 | -0.83 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 55.72 | 55.63 | 55.30 | 54.61 | 54.50 |
Diluted EPS Before Non-Recurring Items | 0.36 | 0.00 | 0.02 | -0.29 | -0.02 |
Diluted Net EPS (GAAP) | 0.36 | 0.00 | 0.04 | -0.29 | -0.02 |